Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.42 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.41 |
| ▸ | GHSR | Q92847 | 1/20 | 0.40 |
| ▸ | TEK | Q02763 | 2/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3335653 | 0.88 | SYK (0.45) | MAPK10SYKPIK3CABRAFHTT | |
| SCHEMBL3335192 | 0.87 | TTK (0.47) | MAPK10MAP4K4LIMK1GHSRBRAF | |
| SCHEMBL3334445 | 0.86 | KMT2A (0.46) | MAPK10SYKMAP4K4LIMK1GHSR | |
| SCHEMBL5179372 | 0.85 | TRIM58 (0.41) | MAPK10SYKPIK3CAMAP4K4GHSR | |
| SCHEMBL3340775 | 0.85 | MAPK10 (0.44) | MAPK10MAP4K4LIMK1GHSRBRAF | |
| SCHEMBL3337175 | 0.84 | MOK (0.46) | MAPK10PIK3CAMAP4K4LIMK1GHSR | |
| SCHEMBL3335821 | 0.84 | HPGD (0.44) | MAPK10MAP4K4LIMK1GHSRBRAF | |
| SCHEMBL3338589 | 0.84 | RAB9A (0.52) | MAPK10SYKMAP4K4LIMK1BRAF | |
| SCHEMBL3335960 | 0.83 | KMT2A (0.46) | MAPK10MAP4K4LIMK1GHSRBRAF | |
| SCHEMBL3341282 | 0.83 | GHSR (0.54) | MAPK10MAP4K4GHSRCSF1RSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673929-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-03-18 | — | — | US | claimed |
| US-20100143299-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2010-06-10 | — | — | US | claimed |
| US-8673929-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673929-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673929-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20100143299-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100143299-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100143299-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2008009077-A2 | 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143299-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | OPRD1, IFNAR1, NR4A1 | MAPK10 2778/4885SYK 1709/4885PIK3CA 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.